Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Walking Tests With and Without Extra Oxygen in Pulmonary Vascular Disease

Compares walking on room air versus nasal oxygen in adults with pulmonary hypertension.

Plain-language title generated from the registry record
Registry title: Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)

Key facts

Where
Zurich, SwitzerlandSee the site

Where in Switzerland

  • University Hospital ZurichZurich, SwitzerlandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Silvia Ulrich Somaini
Trial code
NCT07777445
Record updated
9 September 2026
Original description
The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).Read full original descriptionShow less

Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Flow Oxygen Therapy in Patients With Exercise Induced Desaturation Due to Pulmonary Disease

The investigators aim to study the effect of liquid oxygen therapy (4l/min, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).

Inclusion: - Minimum 18 years of age; Written informed consent; Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease; Former desaturation under exercise defined as SpO2-decrease >3%; Treated with a stable drug therapy (with no changes for at least 14 days prior to screening).

Exclusion: - Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 < 6.9 kPa; Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc; Inability or contraindications to undergo the investigated intervention.

ClinicalTrials.gov NCT07777445